NASDAQ:EQ
Equillium Inc. Stock News
$0.662
-0.0180 (-2.65%)
At Close: Jul 03, 2024
Equillium to be included in the Russell Microcap® Index
08:00am, Wednesday, 12'th Jun 2024
LA JOLLA, Calif.--(BUSINESS WIRE)---- $EQ--Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory dis
Equillium Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
08:00am, Wednesday, 05'th Jun 2024
LA JOLLA, Calif.--(BUSINESS WIRE)---- $EQ--Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory dis
Equillium Announces Positive Topline Data from Phase 2 Study of EQ101 in Alopecia Areata
08:00am, Tuesday, 04'th Jun 2024
LA JOLLA, Calif.--(BUSINESS WIRE)---- $EQ--Equillium Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat s
Equillium to Present at the Jefferies Global Healthcare Conference
08:00am, Wednesday, 29'th May 2024
LA JOLLA, Calif.--(BUSINESS WIRE)---- $EQ--Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory dis
Equillium Announces Interim Enrollment Achieved in Phase 3 EQUATOR Study of Itolizumab in Acute Graft-Versus-Host Disease
08:00am, Tuesday, 14'th May 2024
LA JOLLA, Calif.--(BUSINESS WIRE)---- $EQ--Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory dis
Equillium, Inc. (EQ) Reports Q1 Loss, Tops Revenue Estimates
06:36pm, Thursday, 09'th May 2024
Equillium, Inc. (EQ) came out with a quarterly loss of $0.08 per share versus the Zacks Consensus Estimate of a loss of $0.17. This compares to loss of $0.11 per share a year ago.
Equillium Reports First Quarter 2024 Financial Results and Provides Recent Clinical Highlights
04:01pm, Thursday, 09'th May 2024
LA JOLLA, Calif.--(BUSINESS WIRE)---- $EQ--Equillium Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat s
Equillium Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
08:00am, Wednesday, 03'rd Apr 2024
LA JOLLA, Calif.--(BUSINESS WIRE)---- $EQ--Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory dis
5 Stocks That More Than Doubled in Q1 With More Gains Ahead
10:56am, Monday, 01'st Apr 2024
Equillium (EQ), Laird Superfood (LSF), QuantaSing (QSG), Phunware (PHUN) and Arq (ARQ) more than double in the first quarter and are expected to continue their strong performances.
Equillium, Inc. (EQ) Reports Q4 Loss, Tops Revenue Estimates
06:10pm, Monday, 25'th Mar 2024
Equillium, Inc. (EQ) came out with a quarterly loss of $0.07 per share versus the Zacks Consensus Estimate of a loss of $0.17. This compares to earnings of $0.08 per share a year ago.
Equillium Reports on Fourth Quarter and Full Year 2023 Financial Results and Corporate and Clinical Highlights
04:01pm, Monday, 25'th Mar 2024
LA JOLLA, Calif.--(BUSINESS WIRE)---- $EQ--Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat
LA JOLLA, Calif.--(BUSINESS WIRE)---- $EQ--Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory dis
5 Stocks That More Than Doubled in February
10:31am, Friday, 01'st Mar 2024
Janux Therapeutics (JANX), SoundHound (SOUN), ROOT, Equillium (EQ) and CleanSpark (CLSK) more than doubled in February.
5 Top-Ranked Stocks That Have More Than Doubled Year to Date
10:11am, Friday, 23'rd Feb 2024
Amid the broad-market rally, shares of Equillium (EQ), Phunware (PHUN), Super Micro Computer (SMCI), Vaxart (VXRT) and Dianthus Therapeutics (DNTH) have more than doubled this year.
Equillium Announces Update on Multi-Cytokine Inhibitors EQ101 & EQ102 in Development for Alopecia Areata and Celiac Disease
08:00am, Thursday, 21'st Dec 2023
LA JOLLA, Calif.--(BUSINESS WIRE)---- $EQ--Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory dis
